Synthesis and in vitro characterization of [¹⁹⁸Au]Auranofin.

ABSTRACT:

Background

Radiopharmaceuticals offer targeted treatment by combining diagnostic or therapeutic radionuclides with biologically active molecules. Auranofin is the only Food and Drug Administration (FDA) approved gold(I) complex, originally developed for the treatment of rheumatoid arthritis. Recent evidence has highlighted its potential as an anticancer agent due to its ability to disrupt redox signaling, inhibit thioredoxin reductase, and impair glycolytic metabolism. This study aims to incorporate the true theranostic radionuclide ¹⁹⁸Au into the Auranofin scaffold and evaluate its impact in-vitro on cancer cells.

Results

Carrier-added (c.a.)¹⁹⁸Au was produced via neutron activation of ¹⁹⁷Au and subsequently converted into c.a. H [^198</

SUBMITTER: Bhardwaj P 

PROVIDER: S-EPMC12589756 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature